Aerie Pharmaceuticals Logo

R&D

Aerie Pharmaceuticals was founded to discover a drug that targets the main cause of elevated intraocular pressure (IOP) in glaucoma–the diseased trabecular meshwork. This intensive effort led to the design of netarsudil, a Rho kinase (ROCK) inhibitor, and the assembly of a proprietary library of thousands of related molecules.

Our medicinal chemists, biologists, engineers, and clinical researchers are focused on drug candidates that leverage our small-molecule drug discovery, formulation, and drug delivery capabilities.

innovative eye care products

PIPELINE

We are building a global pipeline of innovative eye care therapeutics that address unmet needs in ophthalmology.

MORE
Researcher conducting ophthalmic clinical trials

CLINICAL TRIALS

We have completed and continue to pursue clinical trials that are providing a growing data set on the efficacy and safety of our products.

MORE
Research Bibliography image

RESEARCH BIBLIOGRAPHY

The results of our R&D activities are regularly published in peer-reviewed journals or presented at leading scientific and medical congresses.

MORE
TOP